A randomized subject- and investigator-blinded placebo-controlled pharmacodynamic study of oral LIK066 in overweight and obese women with polycystic ovary syndrome

The purpose of the study is to evaluate whether LIK066 can be developed for the treatment of polycystic ovary syndrome (PCOS) in overweight and obese women. Approximately 24 subjects will be randomized in a 1:1 ratio to LIK066 or placebo (12 subjects on LIK066; 12 on placebo). The treatment period is 2 weeks; dosing is oral, 50 mg of LIK066 or matching placebo three times daily before meals for 14 days and a single dose on Day 15 in the morning before the test meal. Each subject will participate in a screening period of up to 6 weeks, a baseline assessment, a treatment period of 2 weeks, and a follow-up period of about 1 week with an end of study visit on approximately Day 22.

You may be eligible for this study if you meet the following criteria:

• Conditions: TBD, tbd, tbd
• Age: 99 years or below
• Gender: All